NLRP3 inflammasome in the pathogenesis of acute myocardial infarction: a cardiologist's view-Reference-Cited by-同舟云学术

NLRP3 inflammasome in the pathogenesis of acute myocardial infarction: a cardiologist's view

Published:2023-12-28 Issue:4 Volume:29 Page:5649
ISSN:2618-7620
Container-title:Russian Journal of Cardiology
language:
Short-container-title:Russ J Cardiol

Author:

Ryabov V. V.¹^ORCID,Gombozhapova A. E.¹^ORCID,Samoilova Yu. O.²^ORCID,Sirotina M. A.²^ORCID,Malysheva D. A.³^ORCID,Maslov L. N.²^ORCID

Affiliation:

1. Cardiology Research Institute, Tomsk National Research Medical Center; Siberian State Medical University

2. Cardiology Research Institute, Tomsk National Research Medical Center

3. Siberian State Medical University

Abstract

Within five years after myocardial infarction (MI), a third of patients have secondary major adverse cardiovascular events (MACEs). The first randomized clinical trials to show the effectiveness of anti-inflammatory strategies in the prevention of MACEs are CANTOS, COLCOT and LoDoCo2. These studies have identified an effective therapeutic target — the NLRP3 inflammasome. The results of COLCOT and LoDoCo2 led to colchicine becoming the first anti-inflammatory drug to be included in clinical guidelines for the treatment of patients with coronary artery disease (CAD). However, considering colchicine in routine clinical practice requires the cardiologist to have knowledge of the basic molecular mechanisms of inflammation in cardiovascular diseases. The review discusses current data on inflammation and the NLRP3 inflammasome in the pathogenesis of CAD and MI, results and issues of their application in clinical cardiology.

Publisher

Silicea - Poligraf, LLC

Reference47 articles.

1. Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. The Lancet. 2017;389(10065):197-210. doi:10.1016/S0140-6736(16)30677-8.

2. Camacho X, Nedkoff L, Wright FL, et al. Relative contribution of trends in myocardial infarction event rates and case fatality to declines in mortality: an international comparative study of 1·95 million events in 80·4 million people in four countries. Lancet Public Health. 2022;7(3):e229-e239. doi:10.1016/S2468-2667(22)00006-8.

3. Vaduganathan M, Mensah GA, Turco JV, et al. The Global Burden of Cardiovascular Diseases and Risk. J Am Coll Cardiol. 2022;80(25):2361-71. doi:10.1016/j.jacc.2022.11.005.

4. Ritsinger V, Nyström T, Saleh N, et al. Heart failure is a common complication after acute myocardial infarction in patients with diabetes: A nationwide study in the SWEDEHEART registry. Eur J Prev Cardiol. 2020;27(17):1890-901. doi:10.1177/2047487319901063.

5. Steen DL, Khan I, Andrade K, et al. Event Rates and Risk Factors for Recurrent Cardiovascular Events and Mortality in a Contemporary Post Acute Coronary Syndrome Population Representing 239 234 Patients During 2005 to 2018 in the United States. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2022;11(9):e022198. doi:10.1161/JAHA.121.022198.